MedTrace Logo

DAA Therapy in Pediatric Patients With Chronic Hepatitis C

NCT03481036 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2019-06-17

No results posted yet for this study

Summary

The Mukh-Mantri Punjab Hepatitis C Relief Fund (MMPHCRF) is a public health initiative for prevention and control of hepatitis C in the Punjab state, India. The efficacy of decentralised public health services and safety of 12- or 24-weeks of sofosbuvir (SOF) + ledipasvir (LDV) or SOF + daclatasvir (DCV) with or without ribavirin (RBV) in the treatment of pediatric chronic hepatitis C will be assessed

Conditions

  • Chronic Hepatitis c

Interventions

DRUG

Direct Acting Antivirals

Sofosbuvir and Daclatasvir

DRUG

DAAs in Cirrhotics Genotype 2/3

Sofosbuvir and Daclatasvir with weight based ribavirin

DRUG

DAAs in Cirrhotics Genotye 1,4,5,6

Sofosbuvir and Ledipasvir with weight based ribavirin

Sponsors & Collaborators

  • Directorate of Health and Family Welfare, Punjab

    collaborator OTHER

  • Post Graduate Institute of Medical Education and Research, Chandigarh

    lead OTHER

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
12 Years
Max Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-06-18
Primary Completion
2020-12-31
Completion
2020-12-31

Countries

  • India

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03481036 on ClinicalTrials.gov